Montréal, Canada – 28-08-2023 – bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received Health Canada Approval. This panel rapidly tests for 31 pathogens commonly associated with joint infections and 8 antimicrobial resistance (AMR) genes, optimizing timely antibiotic therapy and stewardship
Canada
All news
MNA Rizqy and Minister Fitzgibbon honor the employees of bioMérieux Canada Inc. with the National Assembly Medal for their exceptional contribution during the COVID-19 pandemic
27 June, 2022The bioMérieux Canada team remained true to its commitment towards public health by ensuring the installation of the BIOFIRE® systems in record time. The team traveled across Canada despite the sanitary restrictions to ensure adequate user training and was able to demonstrate agility and innovation...
MAESTRIA™, a new generation microbiology middleware developed by bioMérieux to optimize laboratory workflow and improve patient care
31 January, 2023
Marcy-l’Étoile, France – February 1st, 2023 – bioMérieux, a world leader in the field of in vitro diagnostics, launches MAESTRIA™. This new generation middleware for the microbiology laboratory aims at providing a central software tool for the workflow management of all routine activities.
bioMérieux strengthens its commitment to fight antimicrobial resistance with the acquisition of Specific Diagnostics, an innovative company focusing on fast AST solution
12 April, 2022
Marcy l’Étoile, France, April 12th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately held U.S. based company that has developed a rapid antimicrobial susceptibility test (AST) system that delivers phenotypic AST directly from positive blood cultures. bioMérieux has held a minority stake in Specific Diagnostics since 2019, and the two companies had signed a co-distribution agreement covering the European market in 2021.
bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system
18 March, 2022
Marcy l’Etoile, France – March 18, 2022 — bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF1 mass spectrometry identification system, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This next generation system for routine microbial identification in minutes is now commercially available in countries that recognize CE-marking and in the United States.
bioMérieux molecular tests efficiently detect SARS-CoV-2 Omicron variant
02 December, 2021
As the incidence of infections with the SARS-CoV-2 Omicron variant (B.1.1. 529) continues to rise, there is much concern about diagnostic tests ability to efficiently detect this multi-mutated form of the COVID-19 virus.
bioMérieux – First-Half 2021 Results
01 September, 2021
bioMérieux announces CE-marking of the new MALDI-TOF mass spectrometry identification system: VITEK® MS PRIME
30 April, 2021
bioMérieux, a world leader in the field of in vitro diagnostics, has announced the CE-marking of VITEK® MS PRIME, the next generation of the VITEK® MS MALDI-TOF1 mass spectrometry system for routine microbial identification in minutes.
bioMérieux – First-Quarter 2021 Business Review
27 April, 2021
bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31, 2021.
BIOFIRE® Respiratory 2.1 (RP2.1) Panel with SARS-CoV-2 obtains De Novo FDA Authorization
18 March, 2021
Marcy l’Étoile (France) – bioMérieux, a world leader in the field of in vitro diagnostics, today announced that BioFire Diagnostics, its subsidiary specialized in molecular syndromic infectious disease testing, has received U.S. Food and Drug Administration (FDA) De Novo authorization for the BIOFIRE® RP2.1 Panel.
bioMérieux – 2020 Financial Results
24 February, 2021